Evidence map›Paper›PMID 30024889›Full record

ArticlePloS one2018

Associations of artificially sweetened beverage intake with disease recurrence and mortality in stage III colon cancer: Results from CALGB 89803 (Alliance).

Brendan J Guercio, Sui Zhang, Donna Niedzwiecki, Yanping Li, Ana Babic, Vicente Morales-Oyarvide, Leonard B Saltz, Robert J Mayer, Rex B Mowat, Renaud Whittom and 15 more

Abstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Review
  7. Article
  8. Review
  9. Recommending ultra-processed oral nutrition supplements for unintentional weight loss: Are there risks?Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition · 2023
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Effect of supplementing fava bean (Saudi journal of biological sciences · 2021
    Article
  15. Article
  16. Article
  17. Article
  18. Sugary drinks and cancer risk.Translational cancer research · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Brendan J GuercioDepartment of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, United States of America.ORCID 0000-0001-6296-2473
Sui ZhangDana-Farber/Partners CancerCare, Boston, Massachusetts, United States of America.
Donna NiedzwieckiAlliance Statistics and Data Center, Duke University, Durham, North Carolina, United States of America.
Yanping LiDepartment of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.
Ana BabicDana-Farber/Partners CancerCare, Boston, Massachusetts, United States of America.
Vicente Morales-OyarvideDana-Farber/Partners CancerCare, Boston, Massachusetts, United States of America.
Leonard B SaltzMemorial Sloan Kettering Cancer Center, New York, New York, United States of America.
Robert J MayerDana-Farber/Partners CancerCare, Boston, Massachusetts, United States of America.
Rex B MowatToledo Community Hospital Oncology Program, Toledo, Ohio, United States of America.
Renaud WhittomHôpital du Sacré-Coeur de Montréal, Montreal, Canada.
Alexander HantelEdward-Elmhurst Healthcare, Naperville, Illinois, United States of America.
Al BensonRobert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States of America.
Daniel AtienzaVirginia Oncology Associates, Norfolk, Virginia, United States of America.
Michael MessinoSoutheast Clinical Oncology Research (SCOR) Consortium, Mission Hospitals, Incorporated, Asheville, North Carolina, United States of America.
Hedy KindlerUniversity of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States of America.
Alan VenookUniversity of California at San Francisco Comprehensive Cancer Center, San Francisco, California, United States of America.
Shuji OginoDana-Farber/Partners CancerCare, Boston, Massachusetts, United States of America.
Emilie S ZoltickSection of Preventive Medicine and Epidemiology, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, United States of America.
Meir StampferDepartment of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.
Kimmie NgDana-Farber/Partners CancerCare, Boston, Massachusetts, United States of America.
Kana WuDepartment of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.
Walter C WillettDepartment of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.
Edward L GiovannucciDepartment of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.
Jeffrey A MeyerhardtDana-Farber/Partners CancerCare, Boston, Massachusetts, United States of America.
Charles S FuchsYale Cancer Center, Yale School of Medicine, New Haven, Connecticut, United States of America.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Member Site CoreU10CA180821 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Evanthia Galanis · 2014 to 2026
$177.3M
Project-006U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · 2014 to 2026
$167.6M
SWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PRIMO N. LARA · 2014 to 2026
$152.1M
Statistics CoreU10CA180882 · NCI · MAYO CLINIC ROCHESTER · PI Sumithra Jay Mandrekar · 2014 to 2026
$115.0M
SWOG NCORP Research BaseUG1CA189974 · NCI · THE HOPE FOUNDATION · PI CHARLES D. BLANKE, DAWN HERSHMAN · 2014 to 2026
$80.6M
Southeast Clinical Oncology Research Consortium, Inc. (SCOR)UG1CA189858 · NCI · SOUTHEAST CLINICAL ONCOL RES CONSORTIUM · PI Judith O Hopkins, William J Irvin · 2014 to 2026
$38.8M
Tissue and Pathology ResourcesP50CA127003 · NCI · DANA-FARBER CANCER INST · PI EL-BARDEESY, NABEEL, SELLERS, WILLIAM R · 2007 to 2023
$33.2M
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer CareUG1CA233180 · NCI · DANA-FARBER CANCER INST · PI Harold John Burstein · 2019 to 2026
$8.6M
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer CareU10CA180867 · NCI · DANA-FARBER CANCER INST · PI BURSTEIN, HAROLD JOHN, KIBEL, ADAM S · 2014 to 2018
$6.2M
Accelerating Transdisciplinary Epidemiology of Colorectal CancerR35CA197735 · NCI · DANA-FARBER CANCER INST · PI OGINO, SHUJI · 2015 to 2021
$6.0M
Multidisciplinary Training Program in Cardiovascular EpidemiologyT32HL125232 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Matthew G. Nayor, Vanessa Xanthakis · 2016 to 2026
$5.0M
NCI NIH HHS K07 CA148894NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA127003NCI NIH HHS R01 CA118553NCI NIH HHS R01 CA149222NCI NIH HHS R01 CA169141NCI NIH HHS R01 CA205406NCI NIH HHS R35 CA197735NCI NIH HHS U10 CA180791NCI NIH HHS U10 CA180820NCI NIH HHS U10 CA180821NCI NIH HHS U10 CA180836NCI NIH HHS U10 CA180867NCI NIH HHS U10 CA180882NCI NIH HHS U10 CA180888NCI NIH HHS UG1 CA189858NCI NIH HHS UG1 CA189974NCI NIH HHS UG1 CA233180NHLBI NIH HHS T32 HL125232
6 · The paper itself

Abstract

purposeObservational studies have demonstrated increased colon cancer recurrence and mortality in states of excess energy balance, as denoted by factors including sedentary lifestyle, diabetes, increased dietary glycemic load, and increased intake of sugar-sweetened beverages. Nonetheless, the relation between artificially sweetened beverages, a popular alternative for sugar-sweetened beverages, and colon cancer recurrence and survival is unknown.

methodsWe analyzed data from 1,018 patients with stage III colon cancer who prospectively reported dietary intake during and after chemotherapy while enrolled in a National Cancer Institute-sponsored trial of adjuvant chemotherapy. Using Cox proportional hazards regressions, we assessed associations of artificially sweetened beverage intake with cancer recurrence and mortality.

resultsPatients consuming one or more 12-ounce servings of artificially sweetened beverages per day experienced an adjusted hazard ratio for cancer recurrence or mortality of 0.54 (95% confidence interval, 0.36 to 0.80) when compared to those who largely abstained (Ptrend = .004). Similarly, increasing artificially sweetened beverage intake was also associated with a significant improvement in both recurrence-free survival (Ptrend = .005) and overall survival (Ptrend = .02). Substitution models demonstrated that replacing a 12-ounce serving of a sugar-sweetened beverage with an isovolumetric serving of an artificially sweetened beverage per day was associated with a 23% lower risk of cancer recurrence and mortality (relative risk, 0.77; 95% confidence interval, 0.63 to 0.95; P = .02).

conclusionHigher artificially sweetened beverage consumption may be associated with significantly reduced cancer recurrence and death in patients with stage III colon cancer. This association may be mediated by substitution for sugar-sweetened alternatives. Further studies are needed to confirm these findings.

Indexed as

AdultAgedAged, 80 and overBeveragesColonic NeoplasmsDietary SucroseEnergy IntakeFemaleHumansMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingProportional Hazards ModelsProspective StudiesRisk FactorsDietary SucroseSweetening Agents

Identifiers

PMID30024889
PMCPMC6053135

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.